Altamira Therapeutics (NASDAQ:CYTO) Stock Price Down 25.9% – Here’s What Happened

by · The Cerbat Gem

Altamira Therapeutics Ltd. (NASDAQ:CYTO – Get Free Report)’s stock price was down 25.9% during mid-day trading on Thursday . The company traded as low as $0.30 and last traded at $0.30. Approximately 753,013 shares were traded during mid-day trading, an increase of 8% from the average daily volume of 697,326 shares. The stock had previously closed at $0.41.

Altamira Therapeutics Trading Down 25.9 %

The stock’s 50-day simple moving average is $0.40 and its two-hundred day simple moving average is $0.72.

Altamira Therapeutics Company Profile

(Get Free Report)

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.

Further Reading